drugset / Trial / NCT00549211

A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.

NCT00549211

Phase 1 Completed 42 enrolled GlaxoSmithKline
RandomizedCrossoverSingle-blindTreatment

Summary

A study conducted on healthy volunteers to determine the safety, tolerability and affect on the human body by experimental drug GSK557296.

Timeline

Start
2007-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epelsiban Small molecule Oral